FEMY — Femasys Share Price
Last trade - 00:00- $31.60m
- $33.55m
- $1.63m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 13.71 | ||
| Price to Tang. Book | 14.12 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 19.4 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -460.53% | ||
| Return on Equity | -182.18% | ||
| Operating Margin | -1091.75% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.04 | 1.18 | 1.21 | 1.07 | 1.63 | 8.65 | 17.42 | 11.89% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.
Directors
- Kathy Lee-Sepsick CHM (54)
- Daniel Currie SVP (57)
- Gary Thompson VFN (64)
- Steven Damon VPR (64)
- Lexy Kelley VPR (49)
- Mimi Zieman VPR
- Wendy Perrow DRC (62)
- John Adams IND (59)
- John Dyett IND (51)
- Charles Larsen IND (69)
- Anne Morrissey IND (55)
- Edward Uzialko IND (70)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 19th, 2004
- Public Since
- June 18th, 2021
- No. of Shareholders
- 145
- No. of Employees
- 69
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 27,239,885
- Address
- 3950 JOHNS CREEK COURT, SUITE 100, SUWANEE, 30024
- Web
- https://www.femasys.com/
- Phone
- +1 7705003910
- Auditors
- KPMG LLP
Upcoming Events for FEMY
Similar to FEMY
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 20:36 UTC, shares in Femasys are trading at $1.16. This share price information is delayed by 15 minutes.
Shares in Femasys last closed at $1.16 and the price had moved by -6.07% over the past 365 days. In terms of relative price strength the Femasys share price has underperformed the S&P500 Index by -15.3% over the past year.
The overall consensus recommendation for Femasys is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreFemasys does not currently pay a dividend.
Femasys does not currently pay a dividend.
Femasys does not currently pay a dividend.
To buy shares in Femasys you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.16, shares in Femasys had a market capitalisation of $31.60m.
Here are the trading details for Femasys:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: FEMY
Based on an overall assessment of its quality, value and momentum Femasys is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Femasys is $8.67. That is 647.41% above the last closing price of $1.16.
Analysts covering Femasys currently have a consensus Earnings Per Share (EPS) forecast of -$0.49 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Femasys. Over the past six months, its share price has underperformed the S&P500 Index by -7.52%.
As of the last closing price of $1.16, shares in Femasys were trading -2.84% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Femasys PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.16.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Femasys' management team is headed by:
- Kathy Lee-Sepsick - CHM
- Daniel Currie - SVP
- Gary Thompson - VFN
- Steven Damon - VPR
- Lexy Kelley - VPR
- Mimi Zieman - VPR
- Wendy Perrow - DRC
- John Adams - IND
- John Dyett - IND
- Charles Larsen - IND
- Anne Morrissey - IND
- Edward Uzialko - IND